Foley Partners Judith Waltz and Antoinette Konski authored an article that appeared in Genetic Engineering & Biotechnology News on July 1, 2011 titled “HHS Puts Stamp on Personalized Medicine.” The authors discuss the Department of Health and Human Services’ (HHS) influence on personalized medicine, stating that HHS has received legal and monetary support which should allow for alternative and creative approaches to better personalized healthcare. They add that HHS will also play a critical role in the regulation of direct-to-consumer marketing of genetic tests, noting that it is important for those in the personalized medicine sector to familiarize themselves with the multiple roles that HHS plays.
Author(s)
Related Insights
20 December 2024
Health Care Law Today
GLP-1 Drugs: FDA “Re-Confirms” Decision Removing Tirzepatide from the Drug Shortage List
On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a Declaratory Order reevaluating and re-confirming that the tirzepatide drug shortage has been resolved. This order revoked and replaced FDA’s October 2, 2024, decision on tirzepatide.
20 December 2024
Manufacturing Industry Advisor
Christmas Came Early: Justice Delivered in Supplier Dispute Over Unjust Enrichment
The AirBoss saga continues… This holiday season, AirBoss Flexible Products Co. received a monumental legal victory, righting a costly wrong in MSSC, Inc. v. AirBoss.
19 December 2024
Health Care Law Today
HIPAA Reproductive Health Care Amendments: Compliance in an Uncertain Enforcement Landscape
The amendments to the HIPAA Privacy Rule designed to protect reproductive health care information are under legal challenge as the compliance date quickly approaches.